CN104313142B - MiRNA-30a is preparing the purposes in diagnostic reagent as tagged molecule - Google Patents
MiRNA-30a is preparing the purposes in diagnostic reagent as tagged molecule Download PDFInfo
- Publication number
- CN104313142B CN104313142B CN201410549236.0A CN201410549236A CN104313142B CN 104313142 B CN104313142 B CN 104313142B CN 201410549236 A CN201410549236 A CN 201410549236A CN 104313142 B CN104313142 B CN 104313142B
- Authority
- CN
- China
- Prior art keywords
- mirna
- aki
- diagnosis
- blood plasma
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
The invention provides a kind of miRNA-30a as the purposes of tagged molecule in the acute injury of kidney reagent of preparation diagnosis contrast medium induction.Present invention also offers miRNA-30a and to combine in miRNA-30e, miRNA-188 any one or two kinds as the purposes of tagged molecule in the acute injury of kidney reagent of preparation diagnosis contrast medium induction.Present invention also offers a kind of test kit, containing miRNA-30a.Early diagnosis CI-AKI is may be used for through experimental verification miRNA-30a.MiRNA-30a is separately for diagnosing the susceptibility of CI-AKI to be 56.3%, and specificity is 94.4%; Be 71.8% with the susceptibility of miR-30e and miR-188 Combining diagnosis CI-AKI, specificity is 88.7%.Above-mentioned marker early diagnosis CI-AKI is adopted to have great application prospect and market outlook.
Description
Technical field
The invention belongs to biomedical sector, particularly relate to a kind of molecular marked compound, miRNA-30a is preparing the purposes in diagnostic reagent as tagged molecule specifically.
Background technology
Other factors except the acute injury of kidney (ContrastInducedAcuteKidneyInjury, CI-AKI) that contrast medium is induced refers to, after contrast medium administration, kainogenesis acute kidney injury or renal insufficiency increase the weight of.CI-AKI is the 3rd cause of disease of iatrogenic acute renal failure, accounts for 11% of iatrogenic acute renal failure, is mainly seen in the patient accepting Percutantnoeus coronary intervention diagnosis and treatment operation at present clinically.In recent years along with the increase of China's Incidence of CHD and extensively carrying out of calcification score technology, the sickness rate of CI-AKI, absolute number of falling ill have and raise trend year by year.
Raise although most of CI-AKI patients is transient serum creatinine level, renal failure is really caused to need the ratio of dialysis treatment to be less than 1%, but CI-AKI patient's while in hospital is dead, the incidence of apoplexy and various cardiovascular event all significantly raises, and long-term survival rate is also starkly lower than the patient without kidney injury performance.The control of CI-AKI is significant to improving patient clinical prognosis.
Research shows, early intervention can improve the chance that renal tubal dysfunction improves, and is the key of control CI-AKI.And the prerequisite of early intervention is early diagnosis.The difficult point of current CI-AKI diagnosis is to lack the early diagnosis biomarker that the susceptibility that in similar acute myocardial infarction, troponin is the same is high, specificity is good.The Case definition used clinically take serum creatinine as foundation, and regulation accepts contrast medium 48-72h serum creatinine absolute value increase more than 0.5mg/dL or CI-AKI is made a definite diagnosis in relative value rising more than 25%.But serum creatinine is not the reliability index of the acute change of a reflection renal function, its concentration before renal function loss 50% can not change, raise 48-72 hour after contrast medium exposes usually, seriously delayed, and affect (ThomsenHS by many Non renal factors such as weight in patients, race, age, or sex, body volume, medicine, muscle metabolism and protein absorptions, etal., BrJRadiol76 (2003) 513-518; TomlanovichS, etal., AmJKidneyDis8 (1986) 332-337; VanBiesenW, etal., ClinJAmSocNephrol1 (2006) 1314-1319).
Some research and inquirement of nearest 10 years novel markings things such as NAGL, IL-18, KIM-1 are as the reliability of CI-AKI early diagnosis index and feasibility (FergusonMA, etal., Toxicology245 (2008) 182-193; DevarajanP, etal., ContribNephrol156 (2007) 203-212).In these diagnostic markers, blood NAGL correlative study is maximum, evaluates relatively better.BachorzewskaGajewska etc. find that PCI postoperative patient blood NGAL obviously raises (Bachorzewska-GajewskaH, etal., KidneyBloodPressRes30 (2007) 408-415) at 4h.Its sensitivity and specific degree are respectively 0.9 and 0.74 (Bachorzewska-GajewskaH, etal.IntJCardiol127 (2008) 290-291).But NAGL stability and specificity poor, be subject to the impact of many variable factors of having deposited, as basic kidney disease and urinary tract infections, and the acute kidney injury that Different factor causes can not be differentiated further, serum creatinine therefore can not be replaced as the diagnostic marker of clinical CI-AKI.
At present in the urgent need to searching out, susceptibility is good, high specificity, be easy to measure, stable that do not affect by other variable biotic factors, the early stage biomarker that contrast medium causes acute kidney injury can be evaluated.
MiRNAs is high conservative, endogenous strand non-coding RNA in a class 23-25 Nucleotide size, evolution.Meanwhile, miRNA is that a class has bioactive tiny RNA.MiRNA is by being combined with the pairing of mRNA, and degraded mRNA or disturb it to translate, plays biological regulation effect (SaalS, etal., CurrOpinNephrolHypertens18 (2009) 317-323).
Research finds, miRNA expresses has tissue specificity.YuLiang, PabloLandgraf etc. study different plant species, different tissues miRNA express spectra respectively.Find that part miRNAs is in specific tissue specific expression or enrichment.Such as, miR-122 is liver specific expression, and miR-133a, miR-499 express (LiangY, etal., BMCGenomics166 (2007) 8) at skeletal muscle, Cardiac-specific.
Meanwhile, miRNAs expresses and has disease specific.Research finds that different types of cancer cell miRNA expression characteristic is different.First Calin etc. find miRNA-15, miRNA-16 down-regulated expression (BarbarottoE, etal., CurrPharmDes14 (2008) 2040-2050) in lymphocytic leukemia.And NozomuYahaihara etc. observe miR-155 high expression level in adenocarcinoma of lung, the low expression of let-7a-2 (YanaiharaN, etal., CancerCell9 (2006) 189-198).The expression demonstrating miRNAs has disease specific.MiRNA expresses also has changes with time, and miRNA express spectra dynamically changes with disease course.JonathanGodwin etc. carry out contrast to kidney defects Reperfu-sion mouse model different time points kidney miRNA express spectra and find, miRNAs presents different variation tendencies.Such as, miRNA-21 raises rapidly in early days at Reperfu-sion, reaches plateau.And miRNA-146a starts to raise (GodwinJG, etal., ProcNatlAcadSciUSA107 (2010) 14339-14344) gradually Reperfu-sion 3-7 talent.
Part research finds that miRNA changes can react in blood plasma in the expression of pathological tissues, organ.Research finds the miR-141 of prostate cancer tissue high expression level in serum of patients with prostate cancer also apparently higher than healthy population, and there is higher Sensitivity and Specificity (MitchellPS, etal., ProcNatlAcadSciUSA105 (2008) 10513-10518).In liver lesion induced by drugs model mice, miRNA-122 down-regulated expression in mouse liver that liver is special, but in blood plasma, express obviously rise, and there is dosage/temporal correlation.In blood plasma, miRNA also has good stability (WangK, etal., ProcNatlAcadSciUSA106 (2009) 4402-4407).Although there is the enzyme of a large amount of degradation of rna in blood plasma, substantially there is not the RNA of long section in blood plasma, miRNA can stable existence with some form in blood plasma.Research finds that the miRNAs in blood plasma all keeps stable (ChenX, etal., CellRes18 (2008) 997-1006) when room temperature (24 hours) and multigelation (8 times).
Just because of tissue, the disease specific of miRNA, determine miRNA with the closely-related characteristic of disease pathology physiological status, as diagnostic marker, there is higher specificity.Simultaneously in blood plasma or serum, miRNA can reflect the change that pathological tissues miRNA expresses.Therefore blood plasma miRNA is more and more paid attention to as a kind of noninvasive, special medical diagnosis on disease marker and is approved.
Have a large amount of research and inquirement status of miRNA in chronic renal disease, comprising (SunH, etal., MolBiolRep37 (2011) 2951-2958 such as POLYCYSTIC KIDNEY DISEASE, diabetic nephropathy, tumor of kidney; KatoM, etal., ProcNatlAcadSciUSA104 (2007) 3432-3437; ZhangZ, etal., FEBSLett583 (2009) 2009-2014; HankeM, etal., UrolOncol28 (2009) 655-661).But pay close attention to the diagnostic marker of blood plasma miRNA as CI-AKI without correlative study both at home and abroad at present.
Whole blood, serum or blood plasma are the most widely used clinical pathway sample source.Search out the contrast medium inducing acute injury of the kidney plasma markers thing that early diagnosis information is provided, the experiment of a kind of diagnostic can be produced, greatly assisted diagnosis and this disease of process.
Summary of the invention
A kind of miRNA-30a is the object of the present invention is to provide to prepare the purposes in diagnostic reagent as tagged molecule, described this purposes solve in prior art the molecular marked compound stability of the acute injury of kidney diagnosing contrast medium to induce and specificity poor, be subject to the technical problem of many variable factor impacts of having deposited.
The invention provides miRNA-30a as the purposes of tagged molecule in the acute injury of kidney reagent of preparation diagnosis contrast medium induction, the base sequence of described miRNA-30a is as shown in SEQIDNO:1.
Present invention also offers miRNA-30a as the purposes of tagged molecule in the acute injury of kidney reagent of preparation early diagnosis contrast medium induction, the base sequence of described miRNA-30a is as shown in SEQIDNO:1.
Further, wherein said early diagnosis refer to contrast medium expose after 4-6 hour.
Present invention also offers miRNA-30a and to combine in miRNA-30e, miRNA-188 any one or two kinds as the purposes of tagged molecule in the acute injury of kidney reagent of preparation diagnosis contrast medium induction, the base sequence of described miRNA-30a is as shown in SEQIDNO:1, the base sequence of described miRNA-30e is as shown in SEQIDNO:2, and the base sequence of described miRNA-188 is as shown in SEQIDNO:3.
Present invention also offers miRNA-30a and to combine in miRNA-30e, miRNA-188 any one or two kinds as the purposes of tagged molecule in the acute injury of kidney reagent of preparation early diagnosis contrast medium induction, the base sequence of described miRNA-30a is as shown in SEQIDNO:1, the base sequence of described miRNA-30e is as shown in SEQIDNO:2, and the base sequence of described miRNA-188 is as shown in SEQIDNO:3.
Present invention also offers a kind of test kit, containing miRNA-30a, the base sequence of described miRNA-30a is as shown in SEQIDNO:1.
The present invention searches out the novel marker miRNA-30a contributing to this disease of early diagnosis in the blood plasma miRNA of CI-AKI patient.
Meanwhile, present invention also offers the acute injury of kidney diagnostic method relating to contrast medium induction, the method comprises the following steps: a) provide the plasma sample obtained by individuality; B) measure contrast medium and expose miRNA-30a change in concentration multiple in Plasma Before And After sample, and c) (b) is diagnosed with CI-AKI be associated.
The diagnostic method that the present invention relates to the acute injury of kidney of contrast medium induction additionally provides another preferred embodiment, the method comprises the following steps: a) measure contrast medium and expose miRNA-30a change in concentration multiple in Plasma Before And After sample, the change in concentration multiple that one or more other miRNA b) optionally measuring CI-AKI in plasma sample mark; And c) be used in the change in concentration multiple measured in step (a) and optional step (b), diagnosis CI-AKI.
As used herein, below each of term there is the implication relevant to it in this part.
Term " individuality " is used in reference to the patient accepting calcification score diagnosis and treatment operation in this article, and these patients do not accept unfractionated heparin anticoagulant therapy, or give unfractionated heparin anticoagulant therapy more than 4 hours.
Term " measurement " is used in reference in this article and comprises microRNA chip, Solexa order-checking, Taqman low density array, real-time fluorescence quantitative PCR or the various MicroRNA detection method based on microballoon.
Term " plasma sample " is used in reference to the patients blood plasma obtained for in-vitro evaluation object in this article, and this blood plasma is hung oneself the centrifugal rear acquisition of individual whole blood of EDTA (working concentration is 1.8mg/ml) anti-freezing.
In preferred embodiments, the present invention relates to by various MicroRNA detection method vitro detection blood plasma miRNA-30a, miR-188 and miR-30e change in concentration, and use the change in concentration diagnosis CI-AKI measured.
The present invention may be used in early days (after contrast medium exposure 4-6 hour) diagnosis CI-AKI through experimental verification miRNA-30a.MiRNA-30a is separately for diagnosing the susceptibility of CI-AKI to be 56.3%, and specificity is 94.4%; Be 71.8% with the susceptibility of miR-30e and miR-188 Combining diagnosis CI-AKI, specificity is 88.7%.Above-mentioned marker early diagnosis CI-AKI is adopted to have great application prospect and market outlook.
The invention described above content, to invention has been detailed description, in order to make the clearer summary of the invention of the present invention of those skilled in the art and technique effect, is described in further details the present invention below in conjunction with the drawings and specific embodiments.
Accompanying drawing explanation
Fig. 1 illustrates the acute injury of kidney marker flow process by the induction of miRNA chip method screening contrast medium.
For detecting by real-timePCR method, Fig. 2 A proves that miRNA-30a is at rat kidney organizing specific expression;
Fig. 2 B retrieves the people delivered to organize miRNAs express spectra document to show miRNA-30a at human kidney tissue specific expression.
Fig. 3 real-timePCR method validation chip results, CI-AKI rat plasma miRNA-30a up-regulated.
Fig. 4 real-timePCR method validation chip results, CI-AKI rat plasma miRNA-30a is 4h rising peaking after contrast medium exposes.
Fig. 5 real-timePCR method proves, CI-AKI rat plasma miRNA-30a raises special relevant to the injury of the kidney that contrast medium is induced.
The level of Fig. 6 real-timePCR Measures compare miRNA-30a in CI-AKI and non-CI-AKI patients blood plasma, proves that CI-AKI patient significantly raises.
Fig. 7 miRNA-30a evaluates as the ROC of CI-AKI diagnosis marker.
Embodiment
Below in conjunction with specific embodiments and the drawings, the present invention is further illustrated.
The target miRNA that embodiment 1 cDNA microarray people kidney specific is expressed
1. build CI-AKI rat model
The present invention is by the method establishment CI-AKI rat model through the hypotonic contrast medium of tail vein injection on the basis of prohibiting water 3 days, diuresis " pre-treatment ".This is a kind of novel C I-AKI rat model that the present inventor sets up, and concrete scheme is shown in pertinent literature (SunSQ, etal.IntJournalofCardiol172 (2014) e48-50).
2.miRNA chip differences expression pattern analysis
1) miRNA chip preparation
On the basis adopting aforesaid method success modeling, leave and take 8 hours CI-AKI rat plasmas, kidneys after modeling, for chip loading.Adopt AgilentmiRNAs10.0version chip technology, carry out loading with blood plasma and kidney total serum IgE, mark with phosphorylation Cyanine3-pCp, then carry out chip hybridization, washing and data gathering.
2) bioinformatic analysis
Chip fluorescence intensity signals value adopts AgilentG4450AAFeatureExtractionSoftware9.5 and AgilentScanControlSoftwareversionA7.0 software to carry out collection analysis.Sample signal value is carried out log2 conversion by raw data and is represented after normalization method (normalization).Sample signal Flag value A (Absent) representation signal and background difference are remarkable, P (Present) representation signal and background difference remarkable.Sample data analysis adopts AgilentGeneSpringsoftware9.0, and by contrasting kidney and the blood plasma chip data of CI-AKI and non-CI-AKI rat, obtain the microRNA of differential expression, result is as shown in table 1.
Table 1.miRNAs expression pattern analysis
3) according to chip data preliminary screening target miRNA
MiRNAs express spectra document (LiangY, etal.BMCGenomics.2007Jun12 is organized by retrieval miRbase (release16) database and the people that delivers; 8:166.), the miRNAs of the special or enrichment of screening CI-AKI rat plasma up-regulated, people mouse homology, kidney is as the early stage candidate diagnosis marker of CI-AKI, and idiographic flow as shown in Figure 1.The target miRNA determined after screening has miRNA-30a, miR-30e and miR-188 tri-, and can emphasis of the present invention has probed into miRNA-30a as CI-AKI early diagnosis marker, also have rated the ability that the multiple miRNAs of associating diagnoses CI-AKI simultaneously.
Above result is the result obtained based on miRNA chip technology, below we adopt more accurate real-timePCR method verify.
Embodiment 2 verifies the specific expressed of target miRNA kidney
With the total serum IgE that the Trizol method extraction rat of classics is respectively organized, real-timePCR detects the expression level that target miRNA respectively organizes rat, simultaneously by retrieving the expression level that the people delivered organizes miRNAs express spectra document contrast people respectively to organize.Fig. 2 is the express spectra result of miRNA-30a in rat (A) and people (B) are respectively organized, and miRNA-30a is all greater than other organs more than 2 times and 2 times in the renal expression amount of rat and people, therefore thinks that this miRNA kidney specific is higher.
The extracting of embodiment 3 blood plasma microRNA
The method that the present invention adopts two steps centrifugal to blood plasma, eliminate the hemocyte in blood and cell debris, RNA extracting adopts mirVanaPARISKit (AppliedBiosystem, P/NAMl556), and this is a kind of test kit being applicable to RNA in blood plasma or serum.The internal reference that in current blood plasma, RNA does not quantitatively generally acknowledge can be used, the present invention adds the ectogenic internal reference cel-miR-39 (miRNA that nematode is expressed in RNA extractive process, this sequence is not expressed in human body), be used for the RT-PCR detected result of correction target miRNA.
Plasma sample pretreatment process: whole blood collection is in EDTA anticoagulant tube (working concentration is 1.8mg/ml), first through 4 DEG C, the centrifugal 10min of 820g, remove hemocyte, supernatant is again through 4 DEG C, and the centrifugal 10min of 16000g, removes cell debris, finally draw supernatant in the centrifuge tube of 1.5mlRNase/DNase-free ,-80 DEG C of packing are frozen for subsequent use.
The concrete steps of RNA extracting are as follows:
1) get 400 μ L blood plasma, add 2 × DenaturingSolution of equivalent, vortex mixes, and places 5 minutes on ice.
2) add the acid-phenol:chloroform with cumulative volume equivalent, vortex mixes 30-60 second, room temperature, centrifugal 5 minutes of maximum speed.
3) careful supernatant of drawing is in new 1.5ml centrifuge tube, and add 100% ethanol of 1.25 times of volumes, vortex mixes.
4) be placed into by the centrifugal column of cleaning in clean collection tube, draw the liquid of previous step in centrifugal column, 10000g, centrifugal 30 seconds of room temperature, abandoned stream crosses liquid, is reapposed in collection tube by centrifugal column.Repeat this step, until all liquid crosses centrifugal column.
5) draw 700 μ LmiRNAWashSolution1 in centrifugal column, 10000g, centrifugal 15 seconds of room temperature, abandoned stream crosses liquid, is reapposed in collection tube by centrifugal column.
6) 500 μ LWashSolution2/3 cross post twice, centrifugal 1 minute of void column.
7) be placed into by centrifugal column in new collection tube, post center adds the nuclease-free water of 100 μ L95 DEG C preheatings, centrifugal 30 seconds of room temperature maximum speed, and the liquid in collection tube is the TotalRNA of extraction, puts-80 DEG C of preservations.
The real-timePCR of embodiment 4 blood plasma microRNA detects
The miRNA detection kit (comprising Reverse Transcriptase kit, specificity miRNA primer and probe, fluorescence quantitative detection kit etc.) of Ambion biotech firm of the U.S. is used to detect the related levels of miR-30e and internal reference cel-miR-39.
Detailed process is as follows:
1. reverse transcription reaction: use TaqmanmicroRNAReverseTranscriptionkit (P/N:4366596) and target miRNA specific reverse transcriptase primer to carry out reverse transcription reaction, concrete steps are as follows:
1) reaction system is prepared: prepare according to table 2
The reaction system of table 2.microRNA reverse transcription
2) reverse transcription reaction: carry out reverse transcription reaction upper, reaction parameter is: 16 DEG C, 30 minutes; 42 DEG C, 30 minutes; 85 DEG C, 5 minutes.
2.real-timePCR reacts: use TaqmanUniversalPCRMasterMix (P/N:4324018) and target miRNA specific probe and primer to carry out quantitative fluorescent PCR reaction.Concrete steps are as follows:
1) reaction system is prepared: the multiple hole of each template-setup of each target miRNA three, reaction system is as shown in table 3.
Table 3.RealtimePCR reaction system
2) Real-timePCR reaction: carry out real-timePCR reaction on the LightCycler480 real-time fluorescence quantitative PCR instrument of Roche company: 95 DEG C of denaturations 10 minutes, loop parameter is 95 DEG C, 15 seconds; 60 DEG C, 1 minute, cycle index was 40.So reaction in triplicate, get fixing fluorescence threshold, the mean value obtained is the CT value of target miRNA in this sample at every turn.
The analysis of 3.real-timePCR result: the CT value that can record target miRNA and internal reference miRNA in sample blood plasma with aforesaid method.Take cel-miR-39 as internal reference, in detecting with PCR, classical 2-△ CT tries to achieve the relative content of target miRNA in sample blood plasma (△ CT is the difference of the CT value of target miRNA and internal reference cel-miR-39), then with 2
-△ △ CTtry to achieve the relative changes multiple (△ △ CT is the difference of postoperative △ CT and baseline △ CT) of target miRNA.
Embodiment 5 verifies the change of target miRNA plasma level
Adopt the chip results of realtimePCR method to target miRNA of above-mentioned blood plasma miRNA to verify, result, as Fig. 3, shows the consistence of both results.
It is more than the checking to chip results, result shows the consistence of chip results and real-timePCR result, ensure that the reliability of the selection result, for the mark whether miRNA can become the diagnosis of contrast medium inducing acute injury of the kidney, gone on to say by the following examples.
The change of embodiment 6 rat CI-AKI model blood plasma miRNA
First the present invention verifies on the animal model of CI-AKI whether target miRNA can become the mark of contrast medium inducing acute injury of the kidney diagnosis.
1. first the present invention has carried out collecting to the blood plasma of different time after modeling and has detected the level change of miRNA-30a in blood plasma, and result is as Fig. 4.MiRNA-30a after modeling 2 hours, blood plasma level obviously raises, and presents maximum at 4-6 hour, starts after 8 hours to decline, and is down to baseline values after 24 hours.
2. because in CI-AKI modeling process, the process factors such as taboo water, contrast medium are related to, the possibility of the non-specific rising of blood plasma miRNA is caused for getting rid of these process factors, the present invention have detected again the level of target miRNA respectively in the rat plasma of modeling group (pre-treatment+contrast medium), pretreated group and contrast medium group, and result is as Fig. 5.MiRNA-30a does not significantly raise in pretreated group and contrast medium group rat plasma, and obviously raise in modeling group rat plasma, show that target miRNA causes learning blood plasma level rising because there is acute injury of kidney, instead of because of the non-specific rising that process factor causes.
The clinical CI-AKI patient of embodiment 7 large sample verifies the change of target miRNA
Above-mentioned animal verification portion shows target miRNA as the diagnosis marker of CI-AKI, can reach peak value in 4-6 hour after surgery, below we will verify on human body.
1. patient cases collects
Plasma sample amounts to 392 examples, wherein 71 routine CI-AKI patients blood plasma, 321 routine non-CI-AKI patients blood plasma.Blood sample is from Renji Hospital Attached to Medical College of Shanghai Jiaotong Univ.'s Cardiological, and blood sample is respectively collected once after patient admits He after visualization for 4-6 hour, and the time of collecting is from year June in July, 2013 to 2014.According to patient age (<50,50-70, >70), diabetes (Yes, No), renal function by stages (Stage1,2,3 phases) 71 routine CI-AKI patients are carried out 1:1 pairing, amount to 142 routine patients and include in.Patient clinical case feature is as shown in table 4.
Table 4. clinical characteristic
2) expression and distribution of target miRNA
As a desirable disease diagnosis marker, the background level in blood plasma should be lower, ensure that the susceptibility of Testing index is high, and expression level is relatively homogeneous, ensures the stability of detected result.The present invention have detected the level of target miRNA-30a in blood plasma by real-timePCR method, and result is as table 5.The CT value about 28-29 of result display miRNA-30a before visualization, illustrates that the level in the blood plasma of miRNA-30a in non-CI-AKI patient is lower.Can see that the CT value of miRNA-30a under different clinical risk factors in blood plasma is close in addition, describe the stably express of miRNA-30a in blood plasma.
The baseline values of table 5.miRNA-30a
3) change of miRNA in CI-AKI patients blood plasma
The present invention analyzes the expression of target miRNA blood plasma in CI-AKI and non-CI-AKI group, and as shown in Figure 6, in CI-AKI patient, the expression level of miRNA-30a is significantly higher than non-CI-AKI group.
4) ROC that miRNA diagnoses as CI-AKI evaluates
Carry out ROC analysis according to the data obtained, result is as Fig. 7.It is 0.802 that miRNA-30a can distinguish area under CI-AKI and non-CI-AKI, AUC preferably, and diagnosis accuracy is higher.Under the condition of diagnosis dividing value, miRNA-30a diagnoses the sensitivity of CI-AKI, specific degree is respectively 56.34%, 94.37%, represent that miRNA-30a has higher sensitivity and specific degree as the early diagnosis marker of CI-AKI, can as a kind of potential mark that can be used for diagnosis CI-AKI newly.
5) scope of miRNA-30a level diagnosis CI-AKI
According to the data obtained, in blood plasma, the diagnosis threshold value of miR-30e is 2
-△ △ CT>1.405.After patient's visualization, in 4-6 hour blood plasma, the level of miRNA-30a compares with diagnosis threshold value, is then diagnosed as CI-AKI, is then diagnosed as non-CI-AKI lower than threshold value higher than threshold value.
6) evaluation of blood plasma miRNA Combining diagnosis CI-AKI
For the limitation avoiding single miRNA to diagnose CI-AKI, have detected the change in concentration of blood plasma miR-30e and miR-188 in preferred version of the present invention simultaneously, expression level in result display CI-AKI patient is significantly higher than non-CI-AKI group, under AUC, Line Integral is not 0.805,0.784, and diagnosis accuracy is higher.Obtain according to current data, in blood plasma, the diagnosis threshold value of miR-30e is 2
-△ △ CTthe diagnosis threshold value of >1.428, miR-188 is 2
-△ △ CT>1.343.The present invention proposes a Combining diagnosis model on this basis, namely in patients blood plasma, the concentration of arbitrary miRNA changes and exceedes above-mentioned dividing value and can be diagnosed as CI-AKI, now diagnose the sensitivity of CI-AKI, specific degree is respectively 71.83%, 88.73%, increase when integral diagnostic capability is comparatively used alone miRNA-30a.
Conclusion: as a novel diagnosis marker, blood plasma miRNA-30a just can detect the change of expression level in early days at injury of the kidney, can be used in the early diagnosis of CI-AKI, be better than serum creatinine, it is better to combine other miRNA diagnosis effects.
Claims (3)
1.miRNA-30a is as the purposes of tagged molecule in the acute injury of kidney reagent of preparation diagnosis contrast medium induction, and the base sequence of described miRNA-30a is as shown in SEQIDNO:1.
2.miRNA-30a is as the purposes of tagged molecule in the acute injury of kidney reagent of preparation early diagnosis contrast medium induction, and the base sequence of described miRNA-30a is as shown in SEQIDNO:1.
3. purposes according to claim 2, wherein said early diagnosis refers to the 4-6 hour after contrast medium exposure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410549236.0A CN104313142B (en) | 2014-10-16 | 2014-10-16 | MiRNA-30a is preparing the purposes in diagnostic reagent as tagged molecule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410549236.0A CN104313142B (en) | 2014-10-16 | 2014-10-16 | MiRNA-30a is preparing the purposes in diagnostic reagent as tagged molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104313142A CN104313142A (en) | 2015-01-28 |
| CN104313142B true CN104313142B (en) | 2016-02-03 |
Family
ID=52368451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410549236.0A Expired - Fee Related CN104313142B (en) | 2014-10-16 | 2014-10-16 | MiRNA-30a is preparing the purposes in diagnostic reagent as tagged molecule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104313142B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725632A (en) * | 2009-08-28 | 2012-10-10 | 奥斯瑞根公司 | MiRNA biomarkers of lung disease |
| CN103993093A (en) * | 2014-06-05 | 2014-08-20 | 山东大学齐鲁医院 | Early bladder cancer serum miRNAs specific expression profile and diagnostic model |
| CN104145024A (en) * | 2011-10-21 | 2014-11-12 | 巴塞罗那临床医院 | Plasma microRNAs for the detection of early colorectal cancer |
-
2014
- 2014-10-16 CN CN201410549236.0A patent/CN104313142B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725632A (en) * | 2009-08-28 | 2012-10-10 | 奥斯瑞根公司 | MiRNA biomarkers of lung disease |
| CN104145024A (en) * | 2011-10-21 | 2014-11-12 | 巴塞罗那临床医院 | Plasma microRNAs for the detection of early colorectal cancer |
| CN103993093A (en) * | 2014-06-05 | 2014-08-20 | 山东大学齐鲁医院 | Early bladder cancer serum miRNAs specific expression profile and diagnostic model |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104313142A (en) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104372087B (en) | The diagnosing cancer of liver mark being made up of serum microRNA and diagnostic kit | |
| CN101792793B (en) | Application of miR-182 as glioma generating molecular marker and detective reagent kit thereof | |
| CN104651513A (en) | Gout serum miRNAs biomarkers and method for detecting expression quantity thereof | |
| CN104293914A (en) | MiRNA marker combination for detecting primary hepatocellular carcinoma serum and application thereof | |
| CN104152567B (en) | MiRNA-199a is preparing the purposes in diagnostic kit | |
| CN105603101A (en) | Application of system for detecting expression quantity of eight miRNAs in preparation of product for diagnosing or assisting in diagnosing hepatocellular carcinoma | |
| CN103160588A (en) | Atherosclerosis-related serum miRNA (microribonucleic acid) marker group, and specific primers and application thereof | |
| CN104293908A (en) | Serum miRNA maker assemblage for detecting nonalcoholic fatty liver, and its application | |
| CN105518154A (en) | Detection of brain cancer | |
| CN103074431B (en) | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum | |
| CN104694623A (en) | Plasma miRNA marker for diagnosis of lung cancer and application | |
| CN102534009A (en) | SNP (Single Nucleotide Polymorphism) marker correlated to assistant diagnosis of primary lung cancer and application thereof | |
| CN104278100B (en) | MiRNA-188 is preparing the purposes in diagnostic reagent as tagged molecule | |
| CN105671179B (en) | application of serum microRNA in liver cancer diagnosis and diagnosis kit | |
| CN112063714A (en) | miRNA related to colorectal cancer and application thereof | |
| CN103602747B (en) | Internal reference substance for detecting bladder cancer serum miRNA and its detection primers and use | |
| CN105219841B (en) | A kind of detection kit and its application of lung cancer differential expression microRNA | |
| CN107916291B (en) | It is a kind of for diagnose indication three negative type breast cancers Bone tumours gene diagnosis kit | |
| CN104313142B (en) | MiRNA-30a is preparing the purposes in diagnostic reagent as tagged molecule | |
| CN104313145B (en) | MiRNA-30e is preparing the purposes in diagnostic reagent as tagged molecule | |
| CN105400882A (en) | Serum miRNA markers suitable for diagnosis of ossification of posterior longitudinal ligament and application thereof | |
| US20230167504A1 (en) | Method for aiding detection of pancreatic cancer | |
| CN107746887A (en) | LncRNA compositions and the purposes for preparing diagnosis indication Luminal A type Bone of Breast Cancer transfering reagent boxes | |
| CN107746888B (en) | A kind of gene diagnosis kit shifted for diagnosing indication Her-2 overexpression type Bone of Breast Cancer | |
| CN105671178B (en) | Serum microRNA diagnosing cancer of liver marker and kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160203 Termination date: 20211016 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |